D. Maloney

发表

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

M. Sorror, M. Maris, R. Storb, 2005, Blood.

Accepted Article Preview : Published ahead of advance online publication

D. Maloney, C. Turtle, S. Riddell, 2016 .

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

R. Advani, P. Bierman, L. Gordon, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia.

E. Kimby, K. Anderson, D. Maloney, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab resistance.

D. Maloney, A. Rezvani, David G Maloney, 2011, Best practice & research. Clinical haematology.

Diversity in antibody-based approaches to non-Hodgkin lymphoma

A. Hagenbeek, D. Maloney, C. Gisselbrecht, 2010, Leukemia & lymphoma.

bone marrow transplantation Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic

K. Sullivan, D. Douek, R. Storb, 2011 .

Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.

K. Sullivan, D. Douek, R. Storb, 2001, Blood.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

E. Estey, D. Maloney, D. Porter, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.

R. Levy, M. Kaminski, D. Maloney, 1986, Journal of immunology.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

H. Deeg, P. Hari, M. Sorror, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.

M. Maris, R. Storb, B. Sandmaier, 2002, Blood.

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

M. Wurfel, D. Maloney, C. Turtle, 2017, Cancer discovery.

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Daniel Li, Xueyan Chen, M. Wurfel, 2017, Blood.

Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.

D. Maloney, C. Turtle, S. Riddell, 2020, Blood.

Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.

D. Maloney, J. Gauthier, 2020, Hematology/oncology clinics of North America.

Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells.

M. Bar, M. Sorror, D. Maloney, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

D. Teachey, S. Grupp, D. Maloney, 2018, Nature Reviews Clinical Oncology.

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

S. Heimfeld, D. Maloney, C. Turtle, 2016 .

Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.

R. Levy, D. Czerwinski, D. Maloney, 1998, Blood.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

J. Byrd, S. Heimfeld, B. Wood, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquisition of a CD 19-negative myeloid phenotype allows immune escape of MLL-rearranged BALL from CD 19 CART-cell therapy

D. Maloney, David Wu, C. Turtle, 2016 .

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

D. Maloney, David Wu, C. Turtle, 2016, Blood.

Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab

D. Maloney, S. Riddell, M. Jensen, 2016, Cancer Immunology Research.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

M. Bar, G. Mufti, S. Grupp, 2019, Bone Marrow Transplantation.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

M. Bar, G. Mufti, S. Grupp, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.

S. Heimfeld, B. Wood, D. Maloney, 2015 .

Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.

R. Levy, M. Kaminski, D. Maloney, 1987, Journal of immunology.

Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease.

K. Sullivan, R. Storb, D. Maloney, 1997, Blood.

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy

H. Deeg, B. Sandmaier, D. Maloney, 2011, Bone Marrow Transplantation.

Rituximab: Mechanism of action and resistance.

D. Maloney, Andrea L. Rose, Barbara E. Smith, 2002, Seminars in oncology.

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.

L. Gordon, M. Czuczman, D. Maloney, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

M. Maris, R. Storb, B. Sandmaier, 2007, Blood.

Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma

L. Matza, D. Maloney, A. Powers, 2022, PharmacoEconomics - Open.

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.

D. Maloney, Junlong Li, S. Schuster, 2020, Blood advances.

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

S. Heimfeld, B. Wood, D. Maloney, 2015 .

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Michael L. Wang, L. Gordon, D. Maloney, 2017 .

Anti-CD19 CAR T cell therapy for lymphoma — off to the races!

D. Maloney, 2019, Nature Reviews Clinical Oncology.

ALTERNATIVE DONORS EXTEND TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA WHO LACK AN HLA MATCHED DONOR

S. Montoto, Sonali M. Smith, D. Maloney, 2014, Bone Marrow Transplantation.

Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.

M. Sorror, R. Storb, B. Sandmaier, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects.

D. Maloney, 2007, Hematology. American Society of Hematology. Education Program.

Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning.

M. Maris, R. Storb, B. Sandmaier, 2003, Experimental hematology.

Graft-vs.-Lymphoma Effect in Various Histologies of Non-Hodgkin's Lymphoma

D. Maloney, 2003, Leukemia & lymphoma.

Non-myeloablative hematopoietic stem cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2001, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Jinjuan Wang, Xiaojun Qian, D. Maloney, 2012, Blood.

Immunotherapy in lymphoma

D. Maloney, S. Ansell, F. caligaris-Cappio, 2017, Hematological oncology.

Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.

Sonali M. Smith, M. Norkin, D. Maloney, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma

D. Maloney, S. Riddell, D. R. Cook, 2011, Cancer Immunology, Immunotherapy.

Anti-CD20 antibody therapy for B-cell lymphomas.

D. Maloney, 2012, The New England journal of medicine.

Hodgkin lymphoma, version 2.2015.

R. Advani, P. Bierman, L. Gordon, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma.

D. Maloney, L. Holmberg, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.

B. Sandmaier, D. Maloney, J. Pagel, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comorbidities, alcohol use disorder, and age predict outcomes following autologous hematopoietic cell transplantation for lymphoma

M. Sorror, R. Storb, D. Maloney, 2016 .

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

G. Salles, J. Friedberg, L. Rimsza, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.

M. Sorror, R. Storb, B. Sandmaier, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

S. Smith, D. Maloney, J. Pagel, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

High‐dose CD20‐targeted radioimmunotherapy‐based autologous transplantation improves outcomes for persistent mantle cell lymphoma

D. Maloney, J. Pagel, J. Rajendran, 2015, British journal of haematology.

Brentuximab vedotin administered to platinum‐refractory, transplant‐naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status

D. Maloney, J. Pagel, O. Press, 2015, Hematological oncology.

Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

S. Montoto, P. Hari, D. Maloney, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

D. Czerwinski, D. Maloney, J. Rosenberg, 1994, Blood.

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.

S. Montoto, P. Hari, D. Maloney, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.

D. Maloney, T. Davis, S. Dowden, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects.

D. Maloney, Andrea L. Rose, Barbara E. Smith, 2002, Blood.

A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911

R. Fisher, T. Miller, M. Leblanc, 2003 .

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

M. Maris, R. Storb, B. Sandmaier, 2011, Haematologica.

A phase I / II trial of iodine-131 – tositumomab ( anti-CD 20 ) , etoposide , cyclophosphamide , and autologous stem cell transplantation for relapsed B-cell lymphomas

S. A. Bush, I. Bernstein, J. Eary, 2000 .

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

D. Maloney, F. Hernandez-Ilizaliturri, Timothy R. Mack, 2022, The Lancet.

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.

Matthew J. Frigault, J. Ritz, D. Maloney, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.

D. Maloney, Junlong Li, S. Schuster, 2020, Blood advances.

Second allogeneic hematopoietic cell transplantation for relapse after first allografts

R. Storb, B. Sandmaier, D. Maloney, 2019, Leukemia & lymphoma.

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

M. Sorror, B. Sandmaier, D. Maloney, 2019, Blood advances.

Autologous haematopoietic cell transplantation for non‐Hodgkin lymphoma with secondary CNS involvement

J. Vose, S. Montoto, P. Hari, 2013, British journal of haematology.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.

R. Storb, B. Sandmaier, D. Maloney, 2017, Blood advances.

transplantation Factors affecting antibody levels after allogeneic hematopoietic cell

D. Maloney, B. Storer, M. Boeckh, 2011 .

Factors affecting antibody levels after allogeneic hematopoietic cell transplantation.

D. Maloney, B. Storer, M. Boeckh, 2003, Blood.

Advances in immunotherapy of hematologic malignancies

D. Maloney, 1998, Current opinion in hematology.

Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches.

D. Maloney, 1999, Current opinion in hematology.

In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia.

R. Miller, D. Maloney, J. Mckillop, 1981, Blood.

Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation

D. Maloney, T. Stevens-Ayers, M. Boeckh, 2004, Bone Marrow Transplantation.

M. Maris, R. Storb, F. Baron, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Agranulocytosis unresponsive to growth factors following rituximab in vivo purging.

D. Maloney, Andrea L. Rose, A. Forsythe, 2003, Blood.

Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.

M. Sorror, R. Storb, B. Sandmaier, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).

G. Kraft, T. Kalina, K. Sullivan, 2004, Clinical immunology.

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma

P. Hari, R. Storb, B. Sandmaier, 2018, Haematologica.

CD20-speciﬁc adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

D. Maloney, S. Riddell, P. Greenberg, 2012 .

Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow.

R. Storb, D. Maloney, J. Storek, 1997, Blood.

Kinetics of B, CD4 T, and CD8 T cells infused into humans: estimates of intravascular:extravascular ratios and total body counts.

D. Maloney, D. Shen, J. Storek, 2002, Clinical immunology.

M. Bar, G. Mufti, S. Grupp, 2021 .

Mechanism of action of rituximab.

D. Maloney, 2001, Anti-cancer drugs.

Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis – a single institution experience

R. Storb, B. Sandmaier, D. Maloney, 2017, Leukemia & lymphoma.

Allogeneic hematopoietic cell transplantation after ﬂudarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

M. Maris, R. Storb, B. Sandmaier, 2004 .

Preclinical and phase I and II trials of rituximab.

D. Maloney, 1999, Seminars in oncology.

J. Radich, M. Maris, R. Storb, 2005 .

Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.

R. Storb, B. Sandmaier, D. Maloney, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

transplant conditioning for patients with persistent high-risk B-cell lymphoma

D. Maloney, J. Pagel, J. Rajendran, 2016 .

Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity

D. Maloney, B. Storer, J. Pagel, 2015, Leukemia & lymphoma.

Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma

D. Maloney, J. Pagel, T. Gooley, 2008, Leukemia & lymphoma.

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.

E. Kimby, M. Dimopoulos, D. Maloney, 2006, Clinical lymphoma & myeloma.

The Follicular Lymphoma International Prognostic Index (FLIPI) as Part of a Proposed Prognostic Model for Follicular Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (ASCT).

D. Maloney, J. Pagel, T. Gooley, 2004 .

A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT

D. Maloney, T. Gooley, O. Press, 2016, Bone Marrow Transplantation.

autografts for the treatment of patients with multiple myeloma Allografting with nonmyeloablative conditioning following cytoreductive

R. Storb, D. Maloney, B. Storer, 2013 .

Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)

R. Gottardo, D. Maloney, R. Pierce, 2019, Poster Session Abstracts.

Abstract CT131: A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)

R. Gottardo, D. Maloney, R. Pierce, 2018, Clinical Trials.

High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma

D. Maloney, T. Gooley, O. Press, 2008, Leukemia & lymphoma.

A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation

D. Maloney, T. Gooley, O. Press, 2006, Bone Marrow Transplantation.

Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.

D. Maloney, 2005, Seminars in oncology.

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms

R. Storb, F. Baron, B. Sandmaier, 2019, Haematologica.

Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

M. Sorror, R. Storb, B. Sandmaier, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation

R. Storb, F. Baron, B. Sandmaier, 2006, Transplantation.

Factors Leading to Rituximab Resistance and How to Overcome Them

D. Maloney, 2009 .

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

L. Rimsza, R. Fisher, R. Braziel, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma

D. Maloney, K. Foon, R. Schilder, 1997 .

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

S. de Vos, D. Maloney, I. Yakoub-Agha, 2021, Blood.

Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy

D. Maloney, E. Warren, C. Turtle, 2019, American journal of hematology.

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

M. Maris, R. Storb, B. Sandmaier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.

M. Maris, R. Storb, B. Sandmaier, 2004, Blood.

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

M. Maris, R. Storb, B. Sandmaier, 2007 .

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

M. Maris, R. Storb, B. Sandmaier, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Maintaining life in indolent lymphoma from evidence-based medicine to clinical practicel

A. Hagenbeek, S. Horning, R. Marcus, 2009 .

What is the role of maintenance rituximab in follicular NHL?

D. Maloney, 2008, Oncology.

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

M. Maris, R. Storb, B. Sandmaier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy for Non-Hodgkin’s Lymphoma

D. Maloney, 2001 .

MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study

L. Rimsza, R. Fisher, D. Maloney, 2008 .

Hodgkin lymphoma.

R. Advani, P. Bierman, L. Gordon, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

P. Hari, M. Sorror, M. Maris, 2019, Bone Marrow Transplantation.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

S. Montoto, Sonali M. Smith, P. Hari, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

R. Advani, P. Bierman, L. Gordon, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Alan M. Miller, Sonali M. Smith, R. Vij, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allografting as first transplantation approach in relapsed/refractory grade 1-2 follicular lymphoma provides improved outcomes in long-term survivors Biol Blood Marrow Transplant

Alan M. Miller, Sonali M. Smith, R. Vij, 2015 .

Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.

S. Heimfeld, R. Storb, B. Sandmaier, 2009, Blood.

The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma.

D. Maloney, A. Hatzubai, R. Levy, 1981, Journal of immunology.

Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

M. Maris, R. Storb, B. Sandmaier, 2016 .

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors.

M. Maris, R. Storb, B. Sandmaier, 2020, Blood.

Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect

R. Storb, B. Sandmaier, D. Maloney, 2018, Haematologica.

Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.

M. Bar, R. Storb, B. Sandmaier, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

B. Sandmaier, D. Maloney, T. Gooley, 2021, Blood advances.

90 Y-Ibritumomab tiuxetan, ﬂudarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

R. Storb, D. Maloney, J. Pagel, 2011 .

recurrent B-cell lymphoma anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with Phase I clinical trial using escalating single-dose infusion of chimeric

D. Czerwinski, D. Maloney, Antonio J. Grillo-López, 2011 .

Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2BS) in Patients With Recurrent B-Cell Lymphoma

D. Czerwinski, D. Maloney, T. Liles, 2000 .

Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM

R. Advani, E. Kimby, B. Barlogie, 2014 .

Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies

M. Bar, D. Maloney, C. Turtle, 2021, JCI insight.

Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma

D. Maloney, 2008, Bone Marrow Transplantation.

onmyeloablative Unrelated Donor Hematopoietic Cell ransplantation to Treat Patients with Poor-Risk , elapsed , or Refractory Multiple Myeloma

M. Sorror, M. Maris, R. Storb, 2007 .

Treatment of follicular non-Hodgkin's lymphoma.

D. Maloney, 2005, Current hematology reports.

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

S. A. Bush, I. Bernstein, J. Eary, 2003, Blood.

High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.

D. Maloney, F. Appelbaum, T. Gooley, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.

M. Sorror, M. Maris, R. Storb, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Engraftment of early erythroid progenitors is not delayed after non‐myeloablative major ABO‐incompatible haematopoietic stem cell transplantation

R. Storb, B. Sandmaier, D. Maloney, 2002, British journal of haematology.

Antibody therapy has arrived. Now where does it fit?

D. Maloney, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical status and optimal use of rituximab for B-cell lymphomas.

D. Maloney, P. Mclaughlin, C. White, 1998, Oncology.

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

D. Maloney, C. Turtle, S. Riddell, 2017, Blood.

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

E. Kimby, D. Maloney, M. Hansen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

E. Kimby, M. Dimopoulos, D. Maloney, 2006, Blood.

Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: importance of immunocytochemistry.

D. Maloney, S. Schuetze, P. Weiden, 1999, Blood.

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.

R. Fisher, T. Miller, M. Leblanc, 2003, Blood.

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.

S. A. Bush, I. Bernstein, J. Eary, 2000, Blood.

Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation.

D. Maloney, B. Storer, J. Storek, 2001, Blood.

allogeneic hematopoietic cell transplantation: a study of 193 patients Hepatic injury after nonmyeloablative conditioning followed by

M. Maris, R. Storb, B. Sandmaier, 2013 .

Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.

C. Bloomfield, R. Advani, P. Bierman, 2006, The Journal of the National Comprehensive Cancer Network.

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

J. Friedberg, L. Rimsza, R. Fisher, 2014 .

Nonmyeloablative Hematopoietic Cell Transplantation

C. Flowers, R. Storb, B. Sandmaier, 2001, Current opinion in oncology.

M. Maris, R. Storb, B. Sandmaier, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Stem Cell Transplantation for Multiple Myeloma: Maxi, Mini, or in Between

D. Maloney, W. Bensinger, M. Rotta, 2009 .

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

M. Sorror, M. Maris, R. Storb, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation for the Treatment of Patients with Poor-Risk, Relapsed or Refractory Multiple Myeloma

M. Sorror, M. Maris, R. Storb, 2007 .

Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.

M. Sorror, M. Maris, R. Storb, 2005 .

Allogeneic hematopoietic cell transplantation for multiple myeloma.

R. Storb, D. Maloney, W. Bensinger, 2001, Seminars in hematology.

131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).

H. Deeg, M. Maris, R. Storb, 2005 .

Normal anti-CD3-stimulated proliferation of CD4 T cells at one year after allogeneic marrow transplantation.

D. Maloney, J. Storek, M. Dawson, 1999, Transplant immunology.

Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis

S. Montoto, Sonali M. Smith, P. Hari, 2010 .

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

M. Czuczman, D. Maloney, J. Rosenberg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody.

D. Maloney, I. Gibbs, R. Hoppe, 1996, Blood.

Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma.

D. Maloney, W. Bensinger, L. Holmberg, 2006, Clinical lymphoma & myeloma.

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation

P. Hari, M. Maris, R. Storb, 2014, Haematologica.

Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.

M. Sorror, M. Maris, R. Storb, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

M. Sorror, R. Storb, B. Sandmaier, 2014 .

Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.

M. Bar, P. Hari, R. Storb, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.

D. Maloney, M. Boeckh, J. Storek, 2012, Cytotherapy.

⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.

R. Storb, D. Maloney, J. Pagel, 2011, Blood.

90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution

R. Storb, D. Maloney, J. Pagel, 2014, Nuclear medicine communications.

Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.

R. Warnke, R. Miller, D. Maloney, 1982, The New England journal of medicine.

Follicular lymphoma: a model of lymphoid tumor progression in man.

L. Esserman, A. Zelenetz, D. Maloney, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

The immunobiology of B-cell lymphoma. Studies with anti-idiotype antibodies

R. Warnke, J. Sklar, D. Maloney, 1985 .

Monoclonal Antibodies in the Treatment of Human Leukemias and Lymphomas: Applications of Flow Cytometry

D. Maloney, Richard A. Miller, R. Levy, 1984, Annals of the New York Academy of Sciences.

Monoclonal Antibodies to Human Lymphocytes

A. Oseroff, D. Maloney, M. Link, 1984 .

Strategy to Obtain Monoclonal Anti-Idiotype Antibodies

D. Maloney, Richard A. Miller, B. Camp, 1983 .

Validation of the predictive power of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after allogeneic HCT

M. Sorror, M. Maris, R. Storb, 2006 .

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

transplantation in monkeys Interleukin-7 improves CD4 T cell reconstitution after autologous CD34 cell

D. Maloney, A. Joseph, Hailing Lu, 2013 .

Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys.

D. Maloney, A. Joseph, Hailing Lu, 2003, Blood.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Daniel Li, Jianhong Cao, Xueyan Chen, 2016, The Journal of clinical investigation.

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

H. Deeg, M. Sorror, R. Storb, 2006, Leukemia.

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

P. Hari, R. Storb, B. Sandmaier, 2013, Biology of Blood and Marrow Transplantation.

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

J. Radich, J Wagner, R. Storb, 2001, Blood.

Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.

R. Storb, D. Maloney, B. Storer, 2001, Blood.

Primary Mantle Cell Lymphoma Cell Cultures Soluble Cd40 Ligand Induces Selective Proliferation of Lymphoma Cells In

D. Maloney, B. Storer, M. Lanotte, 2022 .

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.

M. Maris, R. Storb, B. Sandmaier, 2003, Blood.

Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.

S. Heimfeld, D. Maloney, W. Leisenring, 1999, Blood.

Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation

S. Heimfeld, D. Maloney, W. Leisenring, 1999 .

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2003, Blood.

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation.

H. Deeg, M. Maris, R. Storb, 2003, Blood.

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades

P. Hari, M. Sorror, M. Maris, 2020, Haematologica.

Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs

R. Storb, B. Sandmaier, D. Maloney, 2011, Haematologica.

Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation

M. Maris, R. Storb, B. Sandmaier, 2009 .

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

J. Radich, M. Sorror, M. Maris, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

E. Estey, M. Sorror, M. Maris, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.

D. Maloney, C. Turtle, S. Riddell, 2017, Blood.

Interleukin-7 improves reconstitution of antiviral CD4 T cells.

T. Kalina, D. Maloney, D. Liggitt, 2005, Clinical immunology.

Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T‐cell and natural killer‐cell lymphomas

M. Sorror, R. Storb, B. Sandmaier, 2010, British journal of haematology.

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2004, Blood.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Michael L. Wang, L. Gordon, D. Maloney, 2020, The Lancet.

Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.

A. M. Houghton, R. Gottardo, S. Furlan, 2020, Cancer cell.

Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells.

D. Maloney, C. Turtle, S. Riddell, 2018 .

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

S. Heimfeld, B. Wood, D. Maloney, 2016, Science Translational Medicine.

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

M. Czuczman, D. Maloney, J. Rosenberg, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

D. Maloney, C. Turtle, S. Riddell, 2015, Leukemia.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

M. Dhodapkar, S. Grupp, D. Maloney, 2018, Journal of Immunotherapy for Cancer.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

G. Salles, S. de Vos, D. Maloney, 2021, The Lancet. Oncology.

Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.

D. Patrick, D. Maloney, A. Powers, 2021, Blood advances.

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor-T Cell Therapy.

M. Bar, D. Maloney, C. Turtle, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.

M. Sorror, R. Storb, B. Sandmaier, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

M. Sorror, R. Storb, B. Sandmaier, 2008, Cancer.

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

H. Deeg, M. Sorror, M. Maris, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-myeloablative transplantation.

B. Sandmaier, D. Maloney, S. Mackinnon, 2002, Hematology. American Society of Hematology. Education Program.

Rituximab: mechanism of action and resistance.

D. Maloney, Andrea L. Rose, Barbara E. Smith, 2002, Seminars in oncology.

Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.

D. Maloney, F. Appelbaum, J. Pagel, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients.

R. Storb, B. Sandmaier, D. Maloney, 2004, Blood.

De novo generation of CD4 T cells against viruses present in the host during immune reconstitution.

T. Kalina, D. Maloney, D. Dittmer, 2005, Blood.

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

G. Salles, R. Foà, D. Maloney, 2017, Advances in Therapy.

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

D. Maloney, K. Foon, R. Schilder, 1997 .

High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation

S. Heimfeld, J. Panse, M. Sorror, 2005, Leukemia.

and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation

S. Heimfeld, J. Panse, M. Sorror, 2005 .

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.

C. Flowers, M. Sorror, M. Maris, 2004, Blood.

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

C. Flowers, M. Sorror, M. Maris, 2004, Blood.

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.

R. Storb, B. Sandmaier, D. Maloney, 2003, Blood.

Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study.

M. Maris, R. Storb, B. Sandmaier, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.

R. Storb, B. Sandmaier, D. Maloney, 2001, Blood.

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

N. Geller, A. Krishnan, P. Hari, 2011, The Lancet. Oncology.

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

P. Hari, M. Sorror, R. Storb, 2009, Blood.

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.

R. Fanin, M. Boccadoro, R. Storb, 2009, Blood.

Conditioning Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Kinetics of Engraftment in Patients with Hematological Malignancies Given

J. Radich, S. Heimfeld, R. Storb, 2009 .

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

J. Radich, S. Heimfeld, M. Maris, 2004, Blood.

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

K. Cornetta, D. Maloney, C. June, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein.

D. Maloney, R. Levy, W. Vuist, 1994, Blood.

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.

S. Heimfeld, M. Maris, R. Storb, 2003, Blood.

Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas.

R. Warnke, R. Miller, D. Maloney, 1984, Journal of immunology.

A clinical trial of anti-idiotype therapy for B cell malignancy.

R. Warnke, R. Miller, D. Maloney, 1985, Blood.

Lymphoma Regression Induced by Monoclonal Anti-Idiotypic Antibodies Correlates With Their Ability to Induce Ig Signal Transduction and Is Not Prevented by Tumor Expression of High Levels of Bcl-2 Protein

D. Maloney, R. Levy, W. Vuist, 1994 .

Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century.

M. Maris, R. Storb, B. Sandmaier, 2001, Frontiers in bioscience : a journal and virtual library.

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy

Mark R. Enstrom, P. Linsley, R. Gottardo, 2020, Nature Communications.

What is the role for donor natural killer cells after nonmyeloablative conditioning?

R. Storb, F. Baron, B. Sandmaier, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

D. Maloney, J. Rosenberg, C. White, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

I Royston, D. Maloney, K. Foon, 1997, Blood.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

R. Advani, P. Bierman, L. Gordon, 2018 .

A Prognostic Model Predicting Autologous Transplantation Outcomes in Children, Adolescents and Young Adults with Hodgkin Lymphoma

J. Vose, Sonali M. Smith, W. Wood, 2015, Bone Marrow Transplantation.

Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro.

M. Kaminski, D. Maloney, J. Haimovich, 1985, Hybridoma.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio

R. Storb, B. Sandmaier, D. Maloney, 2003, Blood.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Sonali M. Smith, M. Kaminski, J. Friedberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Clinical Cancer Research.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antibody-directed therapies for hematological malignancies.

I. Bernstein, D. Maloney, M. Linenberger, 2002, Trends in molecular medicine.

Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment

M. Czuczman, D. Maloney, P. Mclaughlin, 2000 .

Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells

D. Czerwinski, D. Maloney, Richard A. Miller, 1992 .

Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.

D. Maloney, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies.

D. Maloney, F. Appelbaum, T. Gooley, 2006, International journal of radiation oncology, biology, physics.

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.

D. Maloney, David Wu, O. Press, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

J. Eary, D. Maloney, F. Appelbaum, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Type of post‐grafting immunosuppression after non‐myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor abo incompatibility

R. Storb, B. Sandmaier, D. Maloney, 2002, British journal of haematology.

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

M. Sorror, M. Maris, R. Storb, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation1

D. Douek, D. Maloney, B. Storer, 2002, Transplantation.

The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation

M. Sorror, R. Storb, B. Sandmaier, 2010, British journal of haematology.

Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors

M. Maris, R. Storb, B. Sandmaier, 2006 .

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Allogeneic peripheral blood stem cell graft composition affects early T‐cell chimaerism and later clinical outcomes after non‐myeloablative conditioning

S. Heimfeld, M. Maris, R. Storb, 2005, British journal of haematology.

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma.

R. Storb, D. Maloney, F. Appelbaum, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biology of Blood and Marrow Transplantation

M. Bar, D. Maloney, C. Turtle, 2015 .

Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting.

D. Maloney, J. Storek, M. Dawson, 2000, Blood.

Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.

J. Panse, M. Maris, R. Storb, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

H. Deeg, M. Sorror, M. Maris, 2014, Blood.

Prognostic relevance of ‘early‐onset’ graft‐versus‐host disease following non‐myeloablative haematopoietic cell transplantation

M. Maris, R. Storb, B. Sandmaier, 2005, British journal of haematology.

Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.

M. Maris, R. Storb, B. Sandmaier, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term Outcome of Patients with Multiple Myeloma after Autologous Hematopoietic Cell Transplantation and Nonmyeloablative Allografting Running title: Auto-Allotransplant in Multiple Myeloma

P. Hari, M. Sorror, R. Storb, 2008 .

Phase I/II multisite trial of optimally dosed clofarabine and low‐dose TBI for hematopoietic cell transplantation in acute myeloid leukemia

E. Estey, J. Radich, R. Storb, 2019, American journal of hematology.

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

D. Maloney, C. Turtle, S. Riddell, 2014, Cancer journal.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

P. Hari, M. Sorror, M. Maris, 2011, JAMA.

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy

M. Bar, D. Maloney, C. Turtle, 2021, Blood advances.

Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation.

D. Maloney, P. Mcsweeney, J. Storek, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation.

D. Maloney, J. Storek, M. Dawson, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

M. Sorror, R. Storb, B. Sandmaier, 2007, Blood.

The thymus is typically small at 1 year after autologous or allogeneic T-cell-replete hematopoietic cell transplantation into adults

D. Maloney, J. Storek, B. Porter, 2004, Bone Marrow Transplantation.

Improved Reconstitution of CD4 T Cells and B Cells But Worsened Reconstitution of Serum IgG Levels After Allogeneic Transplantation of Blood Stem Cells Instead of Marrow

R. Storb, D. Maloney, J. Storek, 1997 .

The Impact Of Donor Type And ABO Incompatibility On Transfusion Requirements After Nonmyeloablative Hematopoietic Cell Transplantation (HCT)

M. Sorror, R. Storb, B. Sandmaier, 2010 .

Non‐myeloablative allografting from human leucocyte antigen‐identical sibling donors for treatment of acute myeloid leukaemia in first complete remission

M. Maris, R. Storb, B. Sandmaier, 2003, British journal of haematology.

Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.

C. Flowers, J. Radich, R. Storb, 2001, Annals of the New York Academy of Sciences.

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

R. Advani, E. Kimby, B. Barlogie, 2014, Blood.

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).

G. Salles, D. Maloney, V. Plaks, 2021 .

Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

G. Salles, D. Maloney, V. Plaks, 2020 .

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME

Alan M. Miller, J. Vose, S. Montoto, 2014, Bone Marrow Transplantation.

The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation

D. Maloney, J. Pagel, T. Gooley, 2007, Leukemia & lymphoma.

New treatment options have changed the survival of patients with follicular lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

D. Maloney, J. Kuruvilla, G. Cartron, 2022, Experimental Hematology & Oncology.

Anti-CD 20 Antibody Therapy for B-Cell Lymphomas

D. Maloney, 2012 .

Nonmyeloablative Hematopoietic Cell Transplantation: Status Quo and Future Perspectives

R. Storb, B. Sandmaier, D. Maloney, 2002, Journal of Clinical Immunology.

J. Radich, R. Storb, B. Sandmaier, 2002, International journal of hematology.

macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström

E. Kimby, B. Barlogie, M. Dimopoulos, 2014 .

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

W. Wilson, L. Sehn, Sonali M. Smith, 2016, Journal of the National Cancer Institute.

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.

S. A. Bush, I. Bernstein, J. Eary, 2002, Blood.

Primary Treatment Classical Hodgkin Lymphoma : Lymphocyte-predominant Hodgkin Lymphoma : NCCN Hodgkin Disease / Lymphoma Panel Members Summary of Guidelines Updates

P. Bierman, L. Gordon, D. Maloney, 2001 .

In‐vivo purging of the circulating clonal T‐cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation

D. Maloney, A. Gopal, A. Shustov, 2011, British journal of haematology.

Stem cell transplantation

D. Maloney, 2012 .

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

M. Sorror, R. Storb, B. Sandmaier, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Thomas M. Schmitt, B. Wood, D. Maloney, 2010, Blood.

Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia

R. Storb, D. Maloney, E. Warren, 2009, Clinical Cancer Research.

Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome.

M. Maris, R. Storb, B. Sandmaier, 2003, Experimental hematology.

Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation

M. Sorror, M. Maris, R. Storb, 2015, British journal of haematology.

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

J. Radich, M. Sorror, R. Storb, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma.

A. Nademanee, D. Maloney, P. Armand, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.

D. Maloney, W. Velasquez, R. Dillman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

H. Deeg, D. Maloney, E. Warren, 2019, Clinical lymphoma, myeloma & leukemia.

Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.

D. Maloney, M. Shadman, 2021, Hematology/oncology clinics of North America.

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

M. Sorror, R. Storb, B. Sandmaier, 2010 .

Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

J. Gribben, D. Maloney, C. Hosing, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.

J. Vose, A. Zelenetz, J. Leonard, 2008, Clinical advances in hematology & oncology : H&O.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

J. Vose, S. Montoto, Sonali M. Smith, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

M. Sorror, M. Maris, R. Storb, 2004 .

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.

M. Maris, R. Storb, B. Sandmaier, 2019, The Lancet. Haematology.

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

M. Sorror, R. Storb, B. Sandmaier, 2008, British journal of haematology.

Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.

M. Sorror, M. Maris, R. Storb, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Acute renal failure after nonmyeloablative hematopoietic cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2004, Journal of the American Society of Nephrology : JASN.

Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century.

R. Storb, B. Sandmaier, D. Maloney, 2000, Transplantation proceedings.

Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation.

M. Maris, R. Storb, B. Sandmaier, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.

M. Maris, R. Storb, B. Sandmaier, 2005 .

CAR T Cells.

Zev A. Binder, D. Maloney, D. O’Rourke, 2021, Neurosurgery clinics of North America.

Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies.

R. Storb, B. Sandmaier, D. Maloney, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape

D. Maloney, C. Turtle, 2016, Expert review of hematology.

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

D. Maloney, C. Turtle, R. Lynch, 2022, Journal of cellular and molecular medicine.

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.

M. Bar, D. Maloney, C. Turtle, 2020, Blood.

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

D. Maloney, J. Kuruvilla, Yeonhee Kim, 2021, Journal of Hematology & Oncology.

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

M. Bar, D. Maloney, E. Warren, 2020 .

Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.

D. Maloney, C. Turtle, S. Riddell, 2018 .

in adult B cell ALL patients

S. Heimfeld, B. Wood, D. Maloney, 2016 .

High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL

D. Maloney, E. Warren, C. Turtle, 2022, Transplantation and Cellular Therapy.

Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma

D. Maloney, C. Turtle, R. Lynch, 2022, Leukemia & lymphoma.

Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy.

D. Maloney, C. Turtle, S. Jackson, 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study

J. Bloom, D. Maloney, C. Turtle, 2021, Journal for ImmunoTherapy of Cancer.

Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.

M. Bar, D. Maloney, C. Turtle, 2019, Blood advances.

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

M. Sorror, D. Maloney, C. Turtle, 2022, Blood.

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

M. Kersten, N. Schmitz, P. Riedell, 2018 .

Factors Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy

M. Bar, D. Maloney, C. Turtle, 2020 .

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

D. Maloney, C. Turtle, H. Kiem, 2020 .

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

S. Heimfeld, D. Maloney, C. Turtle, 2016 .

Long‐term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

P. Hari, M. Sorror, M. Maris, 2015, Cancer.

Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity

Matthew J. Frigault, J. Ritz, D. Maloney, 2018, Blood.

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

B. Wood, D. Maloney, F. Appelbaum, 2018, Blood.

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

M. Maris, R. Storb, B. Sandmaier, 2004 .

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy

D. Maloney, C. Jacobson, J. Chavez, 2019, Expert review of hematology.

Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.

D. Maloney, C. Turtle, M. Shadman, 2020, Blood advances.

Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy

D. Maloney, C. Turtle, S. Pergam, 2021, medRxiv.

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

D. Maloney, J. Pagel, O. Press, 2007, Blood.

CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results

D. Maloney, S. Riddell, P. Greenberg, 2012 .

results antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial CD20-specific adoptive immunotherapy for lymphoma using a chimeric

D. Maloney, S. Riddell, P. Greenberg, 2012 .

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

D. Maloney, C. Turtle, S. Riddell, 2020 .

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

L. Rimsza, R. Fisher, T. Miller, 2012, Haematologica.

M. Maris, R. Storb, B. Sandmaier, 2003, British journal of haematology.

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

D. Maloney, E. Warren, C. Turtle, 2018, Blood.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, J. Klein, 2015, Biology of Blood and Marrow Transplantation.

Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.

M. Sorror, R. Storb, B. Sandmaier, 2008, Blood.

Humoral and Cellular Responses to SARS-CoV-2 Vaccines Before and After Chimeric Antigen Receptor-Modified T Cell Therapy

D. Maloney, Meei-Li W Huang, A. Greninger, 2022, Blood Advances.

Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells.

K. Loeb, S. Heimfeld, B. Wood, 2016 .

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignancies

D. Maloney, C. Turtle, T. Gooley, 2019, Transfusion.

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

S. A. Bush, I. Bernstein, J. Eary, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia.

J. Radich, M. Maris, R. Storb, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

R. Storb, B. Sandmaier, D. Maloney, 2007 .

Comparison of two flow cytometric methods enumerating CD4 T cells and CD8 T cells.

D. Maloney, J. Storek, M. Dawson, 1998, Cytometry.

Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML

J. Radich, R. Storb, B. Sandmaier, 2005, Leukemia.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom’s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.

M. Maris, R. Storb, B. Sandmaier, 2006 .

Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).

M. Sorror, M. Maris, R. Storb, 2004 .

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Poor Risk, Relapsed or Refractory Multiple Myeloma.

M. Maris, R. Storb, B. Sandmaier, 2004 .

Treatment of patients (pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL) with nonmyeloablative (NM) conditioning and hematopoietic cell transplantation (HCT) from HLA-matched related (MRD) or unrelated donors (URD)

M. Sorror, M. Maris, R. Storb, 2004 .

M. Maris, B. Sandmaier, D. Maloney, 2004 .

hematopoietic stem cell transplantation Graft-versus-host disease after nonmyeloablative versus conventional

M. Maris, R. Storb, D. Maloney, 2014 .

Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.

R. Storb, B. Sandmaier, D. Maloney, 2021, Transplantation and cellular therapy.

Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.

Brenda, R. Storb, D. Maloney, 2021, Transplantation and cellular therapy.

Low T cell receptor excision circle levels in patients thymectomized 25-54 years ago.

D. Douek, D. Maloney, B. Storer, 2003, Immunology letters.

Incidence of herpesvirus infections following nonmyeloablative allogeneic stem cell transplantation

R. Storb, B. Sandmaier, D. Maloney, 2000 .

Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil

B. Sandmaier, D. Maloney, D. Mager, 2013, Journal of clinical pharmacology.

Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission

D. Maloney, J. Pagel, M. Shadman, 2016, Leukemia & lymphoma.

Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen

M. Maris, R. Storb, B. Sandmaier, 2003 .

Hodgkin disease/lymphoma.

C. Bloomfield, R. Advani, P. Bierman, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Indications for Hematopoietic Stem Cell Transplantation in Patients with Waldenstrom's Macroglobulinemia: A Consensus Project of the EBMT Lymphoma Working Party (LWP)/ European Consortium for Waldenstrom's Macroglobulinemia (ECWM)/International Waldenstrom's Macroglobulinemia Foundation (IWMF)

R. Advani, S. Montoto, C. Buske, 2017 .

Pre‐transplant comorbidity burden and post‐transplant chronic graft‐versus‐host disease

M. Sorror, R. Storb, B. Sandmaier, 2015, British journal of haematology.

Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.

N. Geller, A. Krishnan, P. Hari, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

R. Fisher, T. Miller, M. Leblanc, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

M. Sorror, R. Storb, D. Maloney, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Workshop on Waldenström's Macroglobulinemia Update on treatment recommendations from the Third International

E. Kimby, M. Dimopoulos, D. Maloney, 2008 .

Donor NK Cell Engraftment and Overall and Progression-Free Survivals after Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.

R. Storb, F. Baron, B. Sandmaier, 2005 .

Assessing donor chimerism level among CD3 T, CD4 T, CD8 T, and NK cells predicts subsequent graft rejection, GVHD, and relapse after allogeneic HCT with nonmyeloablative conditioning

S. Heimfeld, M. Maris, R. Storb, 2005 .

What is the role for donor NK cells after nonmyeloablative conditioning

R. Storb, F. Baron, B. Sandmaier, 2007 .

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

M. Bar, P. Hari, R. Storb, 2012 .

High‐dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma

D. Maloney, J. Pagel, T. Gooley, 2008, Cancer.

A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A M

M. Maris, R. Storb, B. Sandmaier, 2009 .

Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.

M. Sorror, R. Storb, B. Sandmaier, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study

A. Krishnan, P. Hari, D. Maloney, 2017, British journal of haematology.

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.

J. Eary, R. Wendt, D. Maloney, 2003, Blood.

Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

M. Sorror, M. Maris, R. Storb, 2008 .

A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index.

M. Sorror, R. Storb, F. Baron, 2004 .

Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI).

M. Maris, R. Storb, B. Sandmaier, 2004 .

A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).

R. Storb, B. Sandmaier, D. Maloney, 2006 .

M. Maris, R. Storb, B. Sandmaier, 2004 .

Nonmyeloablative hematopoietic cell transplantation (HCT) for treatment of patients (pts) with fludarabine-refractory chronic lymphocytic leukemia (CLL) results in prolonged median survival.

J. Radich, R. Storb, B. Sandmaier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).

M. Sorror, M. Maris, R. Storb, 2005 .

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

R. Storb, B. Sandmaier, D. Maloney, 2012 .

Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.

M. Maris, R. Storb, B. Sandmaier, 2004 .

Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.

J. Radich, R. Storb, B. Sandmaier, 2004 .

Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.

S. Heimfeld, J. Panse, M. Sorror, 2004 .

Induction of molecular remissions in chronic myelogenous leukemia (CML) with nonmyeloablative hlaidentical sibling ALLOGRAFTS

R. Storb, B. Sandmaier, D. Maloney, 2000 .

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Sonali M. Smith, M. Kaminski, J. Friedberg, 2016 .

Nonmyeloablative hematopoietic stem cell transplantation

M. Maris, R. Storb, B. Sandmaier, 2001 .

77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity

D. Maloney, M. Borad, S. Kopetz, 2022, Regular and Young Investigator Award Abstracts.

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Not so crystal clear: observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy

D. Maloney, C. Turtle, G. Hughes, 2018, Bone Marrow Transplantation.

Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma

D. Maloney, J. Rosenberg, C. White, 1995 .

Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.

D. Maloney, O. Press, Oliver W. Press, 1998, Oncology.

Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5

G. Salles, D. Maloney, V. Plaks, 2020 .

Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults 60 Years Old With Relapsed or Refractory B-Cell Lymphoma

J. Eary, D. Maloney, F. Appelbaum, 2007 .

A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy.

D. Maloney, M. Ogura, K. Tobinai, 2020, Blood advances.

The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma

D. Maloney, J. Pagel, T. Gooley, 2007, Bone Marrow Transplantation.

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

D. Czerwinski, D. Maloney, T. Liles, 1994 .

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Michael L. Wang, L. Gordon, D. Maloney, 2019, Blood.

Rituximab for follicular lymphoma.

D. Maloney, 2003, Current hematology reports.

Hodgkin Lymphoma Version 1 . 2017 Clinical Practice Guidelines in Oncology

R. Advani, P. Bierman, L. Gordon, 2017 .

639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy

Matthew J. Frigault, D. Miklos, D. Maloney, 2022, Regular and Young Investigator Award Abstracts.

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

M. Kaminski, M. Czuczman, J. Friedberg, 2011 .

Late Effects of CD19-Targeted CAR-T Cell Therapy

M. Bar, D. Maloney, C. Turtle, 2018, Blood.

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

B. Wood, D. Maloney, C. Turtle, 2019, Blood.

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

B. Wood, D. Maloney, S. Riddell, 2019, Blood.

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

D. Maloney, C. Turtle, H. Kiem, 2019, Blood.

High Durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive B-NHL (TRANSCEND NHL 001 Study): A Defined Composition CD19-Directed CAR T Cell Product with Potential for Outpatient Administration

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

D. Maloney, E. Warren, C. Turtle, 2019, Blood.

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

B. Wood, D. Maloney, C. Turtle, 2021, Blood.

New Treatment Options Have Changed the Natural History of Follicular Lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2004 .

Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD 20 Monoclonal Antibody ( IDEC-C 2 BS ) in Patients With Recurrent B-Cell Lymphoma

D. Czerwinski, D. Maloney, T. Liles, 2000 .

variant cells antitumor effect nor prevent the emergence of idiotype-negative the addition of a short course of chemotherapy does not interfere with Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the

D. Czerwinski, D. Maloney, S. Brown, 2011 .

D. Czerwinski, R. Miller, D. Maloney, 1992, Blood.

Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells.

M. Wurfel, D. Maloney, C. Turtle, 2017 .

Antibody therapy for treatment of multiple myeloma.

D. Maloney, T. Hamblin, K. Donovan, 1999, Seminars in hematology.

The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2008 .

Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

R. Storb, B. Sandmaier, D. Maloney, 2013 .

Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT)

M. Sorror, R. Storb, B. Sandmaier, 2011 .

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

M. Sorror, M. Maris, R. Storb, 2008 .

Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

S. Heimfeld, D. Maloney, C. Turtle, 2014 .

Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies

S. Heimfeld, P. Hari, R. Storb, 2016 .

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

P. Riedell, D. Maloney, D. Brander, 2023, The Lancet.

Anakinra for refractory CRS or ICANS after CAR T-cell therapy.

D. Maloney, C. Turtle, E. Nemecek, 2023, Transplantation and cellular therapy.

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

L. Rimsza, R. Fisher, T. Miller, 2009 .

monoclonal antibody Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4

D. Maloney, I. Gibbs, R. Hoppe, 2011 .

Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study

D. Maloney, S. Schuster, F. Locke, 2018, Blood.

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

D. Patrick, D. Maloney, A. Powers, 2019, Blood.

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

Michael L. Wang, L. Gordon, D. Maloney, 2017 .

A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.

D. Maloney, F. Appelbaum, J. Pagel, 2005 .

Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes

M. Sorror, R. Storb, B. Sandmaier, 2011 .

Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).

M. Sorror, R. Storb, B. Sandmaier, 2009 .

Safety and Efficacy of Escalating Doses of 90 Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma

D. Maloney, J. Pagel, J. Rajendran, 2018 .

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Chad A. LaGrange, Geoffrey E. Wile, R. Advani, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer

D. Maloney, M. Borad, T. Welling, 2022, Regular and Young Investigator Award Abstracts.

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center

R. Storb, B. Sandmaier, D. Maloney, 2012, Bone Marrow Transplantation.

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

M. Maris, R. Storb, B. Sandmaier, 2005 .

A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)

D. Maloney, J. Pagel, S. Petersdorf, 2013 .

Comorbidity, Lactate Dehydrogenase (LDH), and Chemosensitivity Are Independent Predictors of Mortality after Autologous Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Lymphoma.

M. Sorror, R. Storb, B. Sandmaier, 2007 .

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

D. Maloney, C. Turtle, S. Riddell, 2015, Leukemia.

Transplantation Infection Rates between Days 100 and 365 after Allogeneic Marrow Low B-cell and Monocyte Counts on Day 80 Are Associated with High

D. Maloney, B. Storer, M. Flowers, 2022 .

Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

M. Sorror, R. Storb, F. Baron, 2005 .

Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen

D. Maloney, F. Appelbaum, R. Maziarz, 2003, Bone Marrow Transplantation.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

M. Maris, R. Storb, B. Sandmaier, 2008 .

IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

D. Maloney, C. Turtle, S. Riddell, 2014, Cancer Journal.

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

M. Czuczman, D. Maloney, P. Mclaughlin, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term outcomes with nonmyeloablative HLA-identical related HCT using tacrolimus and MMF for GVHD prophylaxis

Brenda, R. Storb, D. Maloney, 2021 .

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

J Wagner, R. Storb, B. Sandmaier, 2001, Blood.

Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis

S. Heimfeld, D. Maloney, T. Gooley, 2001, Bone Marrow Transplantation.

Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas

D. Maloney, David Wu, O. Press, 2016, Bone Marrow Transplantation.

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

D. Maloney, C. Turtle, H. Kiem, 2023, Blood advances.

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2012 .

Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001.

Michael L. Wang, L. Gordon, D. Maloney, 2019, Journal of Clinical Oncology.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, D. Maloney, 2015, Biology of Blood and Marrow Transplantation.

Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis

S. Montoto, Sonali M. Smith, D. Maloney, 2013 .

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

R. Advani, P. Bierman, L. Gordon, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

In‐vivo purging of the circulating clonal T‐cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation

D. Maloney, A. Gopal, A. Shustov, 2011, British journal of haematology.

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.

D. Maloney, C. Turtle, S. Riddell, 2023, The Lancet. Oncology.

Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

R. Fisher, J. Radich, T. Grogan, 2004 .

Sonali M. Smith, M. Kaminski, J. Friedberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biology of Blood and Marrow Transplantation

M. Bar, D. Maloney, C. Turtle, 2020 .

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

K. Cornetta, D. Maloney, C. June, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

N. Geller, A. Krishnan, P. Hari, 2011, The Lancet. Oncology.

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help

D. Maloney, D. Porter, S. Nikiforow, 2023, Blood advances.

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

D. Maloney, C. Turtle, R. Maziarz, 2021, Blood.

Indolent lymphomas: current and emerging treatment approaches.

D. Maloney, M. Dreyling, B. Kahl, 2006, Clinical advances in hematology & oncology : H&O.

Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen

D. Maloney, L. Holmberg, Laura Connelly-Smith, 2023, Acta Haematologica.

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

P. Hari, R. Storb, B. Sandmaier, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

J. Panse, M. Maris, R. Storb, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative Allografting for Newly Diagnosed Multiple Myeloma: the Experience of the Gruppo Italiano Trapianti Di Midollo despite Recent Advances, Allografting Re- Mains the Only Potential Cure for Myeloma. from Methods Patients and Donors Supportive Care and Gvhd Grading Transplantation-relate

R. Fanin, M. Boccadoro, D. Maloney, 2022 .

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

D. Maloney, T. Farazi, N. Trede, 2019, Blood.